Lupin''s Ankleshwar Facility Receives EIR from U.S. FDA.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Limited has received an Establishment Inspection Report (EIR) from the U.S. FDA for its Ankleshwar facility in Gujarat, India. The EIR follows a Pre-Approval Inspection conducted from March 2 to March 7, 2026. An EIR with closed status indicates the facility has cleared the regulatory inspection. The company's Managing Director stated this outcome reflects Lupin's focus on quality excellence and regulatory compliance. This facility is one of Lupin's 15 manufacturing sites globally. The clearance is positive for Lupin's ability to supply pharmaceutical products to the U.S. market.
A closed EIR from US FDA is a positive regulatory development that clears the path for potential product approvals from the Ankleshwar facility, supporting Lupin's U.S. market operations and revenue generation capability.